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cation/internal gelation were investigated as a promising
carrier for insulin delivery. The procedure involves the
dispersion of alginate solution containing insulin protein,
into a water immiscible phase. Gelation is triggered in situ by
instantaneous release of ionic calcium from carbonate com-
plex via gentle pH adjustment. Particle size is controlled
through the emulsification parameters, yielding insulin-
loaded microparticles. Particle recovery was compared using
several washing protocols. Recovery strategies are proposed
and the influence on particle mean size, morphology, recov-
ery yield (RY), encapsulation efficiency, insulin release
profile, and structural integrity of released insulin were
evaluated. Spherical micron-sized particles loaded with
insulin were produced. The recovery process was optimized,
improving yield, and ensuring removal of residual oil from
the particle surface. The optimum recovery strategy con-
sisted in successive washing with a mixture of acetone/
hexane/isopropanol coupled with centrifugation. This strat-
egy led to small spherical particles with an encapsulation
efficiency of 80% and a RY around 70%. In vitro release
studies showed that alginate itself was not able to suppress
insulin release in acidic media; however, this strategy pre-
serves the secondary structure of insulin. Particles had a
mean size lower than the critical diameter necessary to be
orally absorbed through the intestinal mucosa followed by
their passage to systemic circulation and thus can be con-
sidered as a promising technology for insulin delivery.
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 2006 Wiley Periodicals, Inc.IntroductionThe challenge of administering insulin orally has been
addressed over the last several decades with a view to helping
ease the pain and stress caused during insulin injections by
the millions of diabetic patients worldwide. Insulin is a
peptide drug and for this reason is still a challenge for oral
dosage, due to enzymatic and/or metabolic degradation in
the gastrointestinal tract.
Much research has been conducted to find an ideal oral
insulin delivery system that mimics the physiologic pattern
of insulin secretion (Carino et al., 2000). To ensure enteric
protection, recent advances in pharmaceutical technology
have led to a growth of innovative formulations such as
liposomes (Takeuchi et al., 1996), microparticles (Morishita
et al., 2004), and nanoparticles (Ma et al., 2005; Mesiha et al.,
2005). In drug delivery, nanoparticles have demonstrated
numerous advantages over conventional formulations
(Sakuma et al., 2001; Soppimath et al., 2001); however,
most techniques for producing small particles involve the
use of organic solvents, heat or vigorous agitation which are
potentially harmful to the structure and consequently
biological activity of proteins (Tiyaboonchai et al., 2003). In
this study, we describe small microparticles produced under
mild processing conditions by using emulsification/internal
gelation technology that has previously been only applied to
the production of larger sized microparticles (Alexakis et al.,
1995; Poncelet et al., 1992; Quong et al., 1998; Ribeiro et al.,
1999). This methodology was substantially modified to
produce micron- and nanometer-sized particles (Reis et al.,
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The main difficulty in obtaining micro- and nanoparticles
by emulsification methods is related to the recovery of oil-
dispersed particles due to the high stability of the resultant
dispersion and due to the difficulty in completely
eliminating residual oil. Recovery of the particles produced
by emulsification-based methods depends largely on the size
of the particles. Relatively large and rigid particles are readily
separated from the dispersion by filtration or decantation
(Arshady, 1990) but as the particle size decreases, the
separation problems are magnified (Magenheim and Benita,
1991). Generally, particles smaller than 10 mm are recovered
by centrifugation (Arshady, 1990).
The aim of this study was to produce small-sized alginate
microparticles by emulsification/internal gelation with a
mean diameter less than 10 mm for potential oral insulin
delivery. The absorption of particles from the intestine is
affected by a number of factors amongst which particle size
is prominent (Saez et al., 2000). The critical particle size to
enable absorption is still the subject of some debate (Norris
et al., 1998) but generally 10mm appears as upper limit (Cho
et al., 1998). An additional consideration for intestinal
transport is the charge carried by the molecule. Due to a
predominance of negatively charged groups around the
intestinal pores (negative sialic acid groups on mucin),
neutral or cationic compounds should pass more easily
through these paracellular aqueous pores compared to
anionic compounds. A discrepancy, however, is observed
since the negatively charged guluronic acid of alginate also
appears to interact with the mucin (Cho et al., 1998; Norris
et al., 1998).
The detailed methodology to produce small-sized alginate
microparticles is described and the effect of particle recovery
procedure onmean size, particle morphology, recovery yield
(RY), encapsulation efficiency of insulin, insulin release
profile, and structural stability of insulin is reported. This
methodology uses alginate as encapsulation matrix. Com-
pared to other polymers, alginate offers additional
advantages in terms of safety and biodegradability,
biocompatibility, availability, and low cost and thus serves
as an excellent candidate for the development of oral insulin
formulation.Table I. Composition of optimized recovery media to isolate
microparticles.
Protocol Composition % (Volume)
A ABS 100
B1 Acetone and ABS 40:60
B2 Acetone, isopropanol, Tween 80, and ABS 30:10:1:59
B3 Acetone, isopropanol, hexane, and ABS 15:10:5:70
B4 Acetone, isopropanol, ether petroleum, and ABS 15:10:5:70
C ABS containing CaCl2 at 50 mM and Tween 80 99:1
A total volume of 100 mL was used in all protocols (ABS means acetate
buffer solution at pH 4.5—USP XXVIII).Materials and methods
Materials
Medium viscosity sodium alginate (approximately 300– 500
cps at 1% w/v, 258C) extracted from Laminaria hyperborea,
Algogel 35411, was supplied by Degussa Texturant Systems
France SAS (Boulogne Billancourt Cedex, France). Ultrafine
calcium carbonate (Setacarb 06, Omya, Orgon, France),
paraffin oil (low viscosity mineral oil from Fischer
Chemicals, Fair Lawn, NJ) and Span 80 (sorbitan mono-
oleate from Fluka, Biochemika, Steinheim, Germany) were
used in the procedure. Human insulin was of recombinant
DNA origin (Insulin Actrapid A/S1 100 IU: 3.5 mg/mL)978 Biotechnology and Bioengineering, Vol. 96, No. 5, April 1, 2007supplied by Novo Nordisk A/S, Bagsværd, Denmark. All
other chemicals used were of reagent analytical grade.Methods
Preparation of Small-Sized Alginate Microparticles
The emulsification-internal gelation technique to form
alginate gel microbeads as described previously (Poncelet,
2001; Poncelet et al., 1999, 1992, 1995; Quong et al., 1998;
Ribeiro et al., 1999) was modified to form alginate particles
ranging from a few microns into the nano-size range. An
aqueous dispersion of insoluble, ultrafine calcium carbonate
crystals (5%, w/v) was sonicated for 30 min to break up
crystal aggregates. Then, 8.3 mL of calcium carbonate
suspension were suspended in an aqueous solution (50 mL)
of alginate (2%, w/v) containing insulin (35 mg). After
homogenization, the resulting dispersion was emulsified
within paraffin oil (aqueous phase/oil phase 50/50, v/v)
containing 1.5 mL of Span 80 by impeller-stirring
homogenization (1,600 rpm). After 15 min emulsification,
20 mL of paraffin oil containing glacial acetic acid (molar
ratio acid-calcium, 3.5) were added to the dispersion and
stirring continued for 60 min to trigger instantaneous
solubilization of calcium from carbonate complex and
concomitant gelation of the alginate particles. Insulin-free
particles were also prepared using the same procedure. Each
batch was prepared in duplicate.Particle Recovery
Oil-dispersed alginate particles were recovered by several
optimized washing protocols namely A, B, and C as
described in Table I. Briefly, 100 mL of acetate buffer
solution at pH 4.5 were added to the biphasic-system
followed by agitation on an orbital shaker (100 rpm,
10 min). Aqueous-dispersed particles were separated by
decantation and the remaining biphasic-dispersed particles
were separated by centrifugation (12,500–80,000g/30 min,
protocol A). Alternatively, particle recovery was achieved by
using the lowest centrifugation rate (12,500g) and different
volume ratios of dehydrating solvents with acetate buffer
instead of 100 mL of only acetate buffer. These protocols
were designated as B1, B2, B3, and B4 as described in Table I.DOI 10.1002/bit
Finally, particle recovery was also achieved by using the
lowest centrifugation rate (12,500g) and acetate buffer
containing calcium chloride with Tween 80 and this
protocol was classified as protocol C. For all protocols,
the final volume of washing media was constant, 100 mL.
After recovery, particles were re-suspended in acetate
buffer at pH 4.5 and stored at 48C. Alternatively, particles
were frozen and lyophilized at 08C for at least 48 h. After
lyophilization, particles were stored at 48C.Removal of Residual Oil From Particles
During recovery, small aliquots of particles were taken after
each washing cycle and observed under optical microscope
(Olympus BH2-UMA) equipped with a Cue-2 image
analyzer (Olympus, Tokyo, Japan) to monitor for the
presence of oil film. The efficacy of the recovery procedures
was evaluated by the number of washing cycles to ensure a
complete removal of oil from the particle surface. This assay
was performed using insulin-free wet particles.Recovery Yield
RY was assessed by measuring the ratio between the
recovered lyophilized particles and the initial mass of solids
according to Equation (1).
RYð%Þ ¼Weight of particles recovered
Initial mass
 100 (1)
Mass of alginate, insulin plus calcium carbonate.Particle Morphology
Mean size was determined by laser diffraction spectroscopy
(LDS) using a Coulter LS130 granulometer. Measurements
were made in triplicate on dilute insulin-loaded alginate
particle suspensions in acetate buffer solution at pH 4.5.
The refraction index applied was the Fraunhofer model.
The shape, surface characteristics, and size of the alginate
particles were also characterized using scanning electron
microscopy, SEM (JSM-840, JEOL Instruments, Tokyo,
Japan). Wet particles were deposited on metal grids using
double-faced adhesive and coated with gold before
observation.Insulin Encapsulation Efficiency
Encapsulation efficiency using alginate as the main
polymer is generally determined after gel network
dissolution with a chelator such as sodium citrate (Ribeiro
et al., 1999). However, in order to perform a preliminary
test of this formulation as potential for oral insulin
delivery, this assay was performed in triplicate under
simulated gastric and intestinal conditions without
enzymes. Ten milligrams of lyophilized insulin-loaded
particles were incubated in 10 mL hydrochloric acid bufferReis eat pH 1.2 (USP XXVIII) under magnetic stirring (100 rpm,
2 h). Aliquots of 1.5 mL were collected and centrifuged.
The supernatant containing released insulin was collected
to be assayed. The remaining insulin-loaded alginate
particles were transferred into a phosphate buffer at pH 6.8
(USP XXVIII) under magnetic stirring (100 rpm, 1 h).
Aliquots of 1.5 mL were collected, centrifuged, and the
supernatant containing released insulin was collected for
protein quantification by spectrophotometry (Cary 11,
Varian, Australia) at 595 nm with the Bradford modified
method using Coomassie plus kit (Pierce, Fisher Canada).
The encapsulation efficiency (EE) of insulin was then
calculated according to Equation (2), assuming that all
insulin encapsulated was released during 3 h:





To characterize the pH-dependent insulin release profiles
of alginate particles under simulated gastrointestinal
conditions, known amounts of particles (10 mg) were
incubated following above conditions. Samples at appro-
priate intervals were withdrawn and assayed for protein.
An equal volume of the hydrochloric acid buffer at pH 1.2
was added to maintain a constant volume. Release was
monitored for 2 h. To simulate the progress of alginate
particles moving from the stomach into the upper small
intestine, the buffer was changed after 1 h to higher pH (pH
6.8), and samples were collected and protein was assayed.
The cumulative insulin release was calculated according to
Equation (3):
CR ¼





W  DrugContent  100
(3)
where Cn is the sample concentration at Tn; V, the total
volume of release medium; Vi, the sampling volume at Ti;Ci,
the sample concentration at Ti (both Vo and Co were equal
to zero), and W the weight of lyophilized particles used for
drug content determination.
To deliver insulin for a long time, the original con-
formation of insulin must be maintained throughout the
whole delivery period. Reversed-phase high-performance
liquid chromatography (RP-HPLC)/HPLC mass and cir-
cular dichroism (CD) were employed to determine
structural/conformational changes of insulin.RP-HPLC and HPLC-Mass
HPLC is a sensitive assay, able to detect a single peptide
bond cleavage. A HPLC system (model HP1100 series,t al.: Design and Recovery of Insulin-Loaded Alginate Microparticles 979
Biotechnology and Bioengineering. DOI 10.1002/bit
Hewlett Packard, Waldbronn, Germany) equipped with
autosampler (Agilent 1100 series, Germany), C18 column
(5 mm, 250 mm 4.6 mm i.d.; Waters Corporation,
Milford, MA) with a Purospher1 STAR RP-18 (precolumn,
5 mm, 4mm 4mm, Merck KGaA, Darmstadt, Germany)
was used to examine insulin aggregation. The mobile phase
was water (solution A) and acetonitrile (solution B) with
0.04% trifluoroacetic acid at a flow rate of 1.2 mL/min. A
linear gradient of 30%–40% B over 5 min was used. Insulin
solution (20 mL) was injected and eluted over 12 min. The
absorbance of the eluant was recorded at 210 nm, and the
area under the curve was measured for calculation of
insulin concentration based on the calibration curves.
Insulin samples for HPLC analysis were prepared by
dissolution in citrate sodium 55 mM prior to analysis.
For HPLC-MS analysis, previous samples were then
analyzed using an Surveyor HPLC system (Thermofinnigan,
San Jose, CA) with degasser, quaternary pump, autosampler,
column oven (all from Thermofinnigan), and diode array
detector (LCQ Advantage, Thermofinnigan). A linear
gradient of 30%–50% solvent B (acetonitrileþ 0.04% v/v
TFA) in solvent A (double-distilled waterþ 0.04% v/v TFA)
over 12 min served as a mobile phase. About 10–20mL of the
samples were separated using a C18 reversed phase analytical
column (X-Terra MS, Waters, 5 mm, 2.1 250 mm). The
XCALIBUR software package (Thermofinnigan) was used
for data acquisition and analysis.Table II. Influence of optimized recovery protocols* on the number of










B1 12,500 6 4.65 1.75 Loss of sphericalCircular Dichroism Spectroscopy
Circular dichroism (CD) spectra were obtained with a Jasco
J-720 spectropolarimeter (Tokyo, Japan) equipped with a
temperature controller to examine the secondary structure
of insulin in particles. Spectra were collected at 258C using a
0.1 cm cell over the wavelength range of 200–260 nm. A
resolution of 0.2 nm and scanning speed (50 nm min1)
with a 4 s response time were employed. Each spectrum
obtained represents an average of three consecutive scans.
Noise reduction, blank buffer subtraction, and data analysis
were performed using standard analysis and temperature/
wavelength analysis programs (Jasco). Samples for CD
analysis were prepared by dissolution in isotonic PBS buffer.
The spectra of insulin samples with concentrations about
10 mM were compared with that of fresh insulin.shape
Irregular shape
Rough surface
B2 1,2500 5 5.57 2.56 Loss of spherical
shape
Irregular shape
B3 12,500 4 4.18 0.28 Spherical particles
Rough surface
B4 12,500 5 68.27 66.55 Spherical particles
Rough surface
C 12,500 9 7.73 3.63 Spherical particles
Smooth surface
*Isopropanol and ABS led to significant irregular shape.Statistical Analysis
Each value of RY and encapsulation efficiency was presented
as mean SD. Multiple comparison between several
protocols was analyzed with a one-way layout analysis of
variance (ANOVA). Post-test comparisons were performed
by the Student-Newman–Keuls method. Statistical analysis
was performed with Sigma Stat (version 2.03; SPSS Inc.
Chicago, IL). A P< 0.05 was taken as the criterion of
significance.980 Biotechnology and Bioengineering, Vol. 96, No. 5, April 1, 2007Results and Discussion
The objectives of the present study were to produce
small-sized insulin-loaded alginate microparticles by
emulsification/internal gelation, and to develop a recovery
procedure with respect to defined particle morphology and
encapsulation efficiency of insulin. Recovery of larger
alginate microspheres produced by a similar procedure
has been demonstrated by partitioning into a calcium
chloride solution containing surfactant (Poncelet, 2001;
Ribeiro et al., 1999) but this procedure was ineffective in
the recovery of particles less than 10 mm, required for the
present study. For purposes of developing an oral dosage
form of insulin, an optimum recovery procedure would
be determined by high particle recovery efficiency, produc-
tion of discrete particles with mean diameter less than
10mm, and through high encapsulation efficiency of insulin.Recovery Efficiency of Particles
The particle recovery efficiency of the various procedures
was evaluated both by its capacity to eliminate residual oil
and oil droplets and by RY. Oil-dispersed particles were
recovered by a washing step associated with centrifugation.
Concerning the efficiency of residual oil removal, protocol A
required fewer centrifugation/wash cycles (from 9 to 7)
when higher centrifugation rates were applied as described
in Table II. It was determined that seven wash cycles were
adequate to eliminate the residual oil with 55,000–80,000g as
illustrated microscopically by Figure 1a and b. No additional
benefit was demonstrated with more than seven wash cycles.
Protocol C required the same number of wash cycles as
protocol A with 12,500g, and thus no additional advantage is
achieved with this procedure. In contrast, the number of
centrifugation cycles coupled with dehydrating solvents wasDOI 10.1002/bit
Figure 1. a: Example of oil droplets on the alginate particles. b: Photomicrograph
of insulin-free alginate particles following seven wash cycles using protocol A.
Figure 2. Protocol B3: Photomicrograph of insulin-free alginate particles follow-
ing four wash cycles.lower (<7 cycles). The association between centrifugation
and dehydrating solvents decreased the number of cycles
with minimal handling. The protocol with a lowest number
of wash cycles was B3 with four cycles and residual oil was
completely removed as seen in Figure 2.Recovery Yield
Important differences were found in the RY amongst the
different protocols. Yield with protocol A was lower than
50% and an increase was observed (A12,500<A55,000<
A80,000) when the centrifugation speed increased from
12,500 to 80,000g as seen in Figure 3. However, differences
between three groups were not statistically significant.Reis eHigher centrifugation force resulted in the recovery of a
larger fraction of the particles, however a careful balance is
required to minimize stress on the particles or on the
protein. The maintenance of the structural integrity of a
therapeutic protein is essential for its efficacy in relation to
physiological and pharmacological activity (Brange et al.,
1992).
Concerning protocol B and comparing to protocol A, a
significantly higher RY was obtained using dehydrating
solvents coupled with centrifugation. There were significant
statistical differences between these two protocols with
P¼ 0.0011. Considering that the preparation takes place in
an oily dispersion, the particles are more highly mobile with
a low viscosity solvent such as acetone and isopropanol. An
increase in RY (around 15%–25%) was obtained for
protocols B1, B2, B3, and B4 showing that the use of
isopropanol and acetone significantly increased the RY as
illustrated in Figure 3. Both solvents are dehydrating and
miscible with both the water present in the particles and the
hydrophobic suspension medium (Arshady, 1990). Alginate
particles contain high water content and due to a partition
phase phenomenon, internal water is extracted, resulting in
dry particles which lose affinity with the interface of the
emulsion medium and readily precipitate. Moreover, the
elimination of these solvents is relatively easy. Finally, either
hexane or ether did not significantly modify the RY. These
solvents only remove strongly bound contaminants such as
residual oil as previously described (Miyazaki et al., 2003;
Ramdas et al., 1999) but did not affect the RY.
Finally, protocol C had the same RY as protocol A12500
having no influence on the RY. The presence of surfactant
led to amilky suspension followed by a difficult visualization
of the particles. As a result, a considerable quantity of the
particles was lost.t al.: Design and Recovery of Insulin-Loaded Alginate Microparticles 981
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Figure 3. Influence of several recovery protocols on the recovery yield (RY) of alginate particles. Each value represents Mean SD, n¼ 2. *Significant differences from
protocols A12,500 and C (P< 0.05). **Significant differences from protocols A55,000, A80,000 (P< 0.05).
Figure 4. SEM photograph of insulin-loaded alginate particles recovered
exclusively by centrifugation (magnification 1,400).Particle Size
Small-sized insulin-loaded alginate microparticles recovered
through the various protocols had mean diameters varying
from 4.2 mm to those forming significant agglomerates with
mean diameters to 135 mm. In the case of protocol A, no
differences were observed in terms of particle mean size with
an increase of centrifugal force. In contrast, the particle
mean size changed as different mixtures of solvents were
applied as seen in Table II. Acetone has been applied to break
nanoemulsions (Zhi et al., 2005). It is a water-miscible
solvent used as a recovery agent due to its psychochemical
properties and pharmaceutical acceptability with regard to
toxicity (Alle´mann et al., 1993). However, when it is used
with large volumes, particles tend to aggregate (protocol
B1).When using isopropanol and acetone (protocols B2, B3,
and B4), the size of the particles slightly decreased and
aggregation did not occur except for B4. Isopropanol has
also been used as solvent to prepare nanoparticles (Schubert
and Muller-Goymann, 2003) and it has been show to
influence size of alpha-Fe ultrafine particles (Wang et al.,
2000). On the other hand, ether led to some agglomeration
and consequently led to an increase in the mean particle
diameter (protocol B4). In contrast, adding hexane
(protocol B3) did not alter the mean diameter nor was
aggregation observed. Hexane with low boiling point and
low-toxicity is a desirable organic solvent in many
applications (Chen et al., 2003). It is easily removed from
the formulation due to high volatility (Chen et al., 2003),
and it has also been applied in insulin bioactive formulations
(Vladisavljevic and Williams, 2005). Finally, a recovery
procedure involving emulsifier in a high calcium medium
was also tested (protocol C) and no influence on the mean
particle size was observed.982 Biotechnology and Bioengineering, Vol. 96, No. 5, April 1, 2007Morphological Characterization
The structure of insulin-loaded particles was examined by
SEM. Photomicrographs showed that variations in recovery
parameters had an important effect on particle appearance.
The exclusive use of centrifugation for particle recovery did
not change the spherical shape or smooth surface of the
insulin-loaded alginate particles, as illustrated in Figure 4. A
mixture of acetone/acetate buffer solution (B1) or acetone/
isopropanol/Tween 80/acetate buffer solution (B2) caused a
significant change in particle shape and surface morphology
as seen in Figure 5a and b, respectively. B3 showed relativelyDOI 10.1002/bit
Figure 5. SEM photographs of insulin-loaded alginate particles recovered through protocols B1 (a, magnification 350), B2 (b, magnification 1,500), B3 (c, magnification
11,000), and small agglomerate of B4 (d, magnification 950).uniform and spherical particles, but with a rough surface as
demonstrated in Figure 5c. The roughness was once more
due to use of dehydrating solvents. Water extraction appears
to change the alginate network. Also, protocol B4 partially
maintains the particle spherical shape and also led to a rough
particle surface as illustrated in Figure 5d. Protocol C
produced particles with good sphericity and smooth surface
as shown in Figure 6. The smooth and dense particle surface
could be due to residual surfactants, as observed previously
(Magenheim and Benita, 1991).Insulin Encapsulation Efficiency
Centrifugal force had some influence on encapsulation
efficiency as shown in Figure 7. In contrast, the encapsula-Reis etion efficiency with protocols B and C changed considerably
from B2 (acetone, isopropanol, Tween 80, and acetate buffer
solution)<B1 (acetone and acetate buffer solution)<C
(calcium chloride and Tween 80)<B4 (acetone, isopropa-
nol, ether, and acetate buffer solution)<B3 (acetone,
isopropanol, hexane, and acetate buffer solution). Between
B3 and B2, there was a significant statistical difference
(P¼ 0.0365). Compared to protocol A, the efficiency values
of protocol B could be explained by several factors. The
number of wash cycles with protocol B was lower than
protocol A which can suggest less protein losses. As well, the
alginate surface was strongly modified. A rough surface
could be responsible for the small loss of protein during
washing and explain the higher encapsulation efficiencies
compared to protocol A. As well, it may be possible thatt al.: Design and Recovery of Insulin-Loaded Alginate Microparticles 983
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Figure 6. SEM photomicrograph of insulin-loaded alginate particles recovered
through protocol C (magnification 5,000).dehydrating solvents alter alginate permeability. However,
the volume of dehydrating solvents had a significant
influence on this parameter. During washing, insulin may
be drawn out of the particles following the extracted water.
Thus the balance between insulin retention and water
extraction must be considered. In fact, high amounts of
acetone (40 mL for B1 and 30 mL for B2) caused some
diffusive loss of encapsulated insulin, and the mixture of
30 mL of acetone and 10 mL of isopropanol led to higher
insulin diffusive loss compared to 40 mL of acetone. By
reducing the volume of acetone to 15 mL (B3 and B4), theFigure 7. Influence of recovery protocols on the encapsulation efficiency of insu
differences from B2 (P< 0.05).
984 Biotechnology and Bioengineering, Vol. 96, No. 5, April 1, 2007encapsulation yield slightly increased. The more suitable
protocol was B3 with highest encapsulation efficiency. As
well, the presence of calcium in the washing medium in
protocol C also led to higher encapsulation efficiency.
Structurally, calcium ions interact with alginate residues
within alginate electronegative cavities (Braccini and Perez,
2001). Higher calcium levels in the medium may have led to
additional cross-reaction between the interchain COO
groups. Calcium chloride has been applied in order to
reduce particle swelling and the resulting diffusive loss of the
encapsulant (Vandenberg et al., 2001). Consequently,
inclusion of CaCl2 in the washing medium could be
desirable to preserve the alginate gel network. Lastly, all
recovery strategies to isolate particles were performed by
using acetate buffer at pH 4.5 as washing medium. In fact,
the washing medium pH is an important factor for protein–
polymer interaction and consequently, encapsulation
efficiency. At pH 4.5, the interactions between alginate
and insulin are very favorable since they were oppositely
charged (pI of insulin 5.3 (Chien, 1996) and alginate pK
3.38 and 3.65 for M and G residues, respectively, Draget
et al., 1994). As well, the intrinsic nature of this
emulsification-based methodology and the high hydrophilic
nature of the protein could also explain the resultant
encapsulation efficiencies.Release Profile
Figure 8 depicts release profiles of insulin from particles
under simulated gastric and intestinal conditions. At low
gastric pH, insulin was rapidly released from tested
formulations (burst release around 100% at 5 min) probably
due to rapid ion-exchange (Hþ and Ca2þ). No significantlin-loaded alginate particles. Each value represents MeanSD, n¼ 3. *Significant
DOI 10.1002/bit
Figure 8. Release profiles of insulin alginate particles (protocols A (–), B1 (-&-), B2 (-~-), B3 (--), B4 (--*--), and C (-&-) at two different pH conditions depending on time.
Experiments were performed in hydrochloric acid at pH 1.2 followed phosphate buffer at pH 6.8.
Figure 9. Reverse phase HPLC chromatographs of a reference solution of insulin samples (a) and the insulin obtained from alginate particle dissolution: protocols A (b), B1
(c), B2 (d), B3 (e), B4 (f), and C (g). Measurements were run in triplicate with good reproducibility though only graphs of one experiment are presented.
Reis et al.: Design and Recovery of Insulin-Loaded Alginate Microparticles 985
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Figure 10. HPLC-Mass representative chromatographs of a reference solution of insulin sample (a) and an example of chromatogram of insulin obtained from alginate
particle dissolution obtained by recovery tested protocols (b).
986 Biotechnology and Bioengineering, Vol. 96, No. 5, April 1, 2007
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differences were observed for each protocol. The value of
insulin released was constant even after changing the
medium to near neutral conditions. This fact may suggest
the co-existence of simultaneous mechanisms. pH-depen-
dent insulin release as well as alginate porosity may have a
significant influence on the insulin release profile. There are
many parameters that are used to control the release rate of
drug from polymeric drug carrier systems. Ongoing research
will developed strategies to obtain controlled insulin release
profile.RP-HPLC and HPLC-MS Analysis
Maintaining protein stability and minimizing aggregate
formation during processing is critical in providing safe and
efficacious protein therapeutics with long shelf lives. Insulin
consists of 51 amino acids with a molecular weight of 5,800
g/mol and degrades rapidly in acid medium at Asn 21, while
in slightly acid or alkaline medium deamination takes place
at residue Asn B3 (Oliva et al., 2000). Two techniques were
applied to determine the stability of insulin: RP-HPLC and
HPLC-Mass. A shift of the retention time of insulin on RP-
HPLC chromatogram is an indication of insulin aggrega-
tion. A freshly prepared insulin solution had a retention
time of 4.8 min. The chromatogram obtained by insulin
released from alginate particles highlighted a single peak
identical to that of a reference solution of insulin. The same
retention time was obtained for all formulations indicating
that insulin was preserved during the particle manufacture
and recovery as shown in Figure 9. The HPLC-Mass
chromatograms of reference insulin solution and insulin
released from alginate particles were similar as shown in
Figure 10a and b. HPLC-MS analysis showed that no high
molecular weight transformation products were formed.Figure 11. Effect of various recovery protocols on the CD spectra of insulin in
solution (10 mM) and insulin released from nanospheres formulated (10 mM) in PBS at
7.4 and 258C: (a) protocol A, (b) insulin non-encapsulated (reference solution), (c–f)
protocols B1, B2, B4, and C, and (g) protocol B3.Secondary Structure of Insulin Released
Preservation of the structural integrity of a protein drug
after release is crucial for its biological efficacy. Thus, the
secondary structure of insulin released from particles was
investigated using CD. Figure 11 shows the far UV CD
spectra of the diluted solutions of insulin released from
alginate particles and recovered by various protocols and
one diluted insulin reference solution (insulin non-
encapsulated). The CD spectrum of insulin non-encapsu-
lated in PBS, at pH 7.4, shows two minima at 209 and 224
nm. These results were in close agreement with results
presented by other studies (Tiyaboonchai et al., 2003). There
was minor deviation of the negative maximum at about 216
nm for protocol A. Protocols B1, B2, B4, and C produced
similar spectra nevertheless they were different from the
reference solution especially with attenuated second mini-
mum. The secondary structure for insulin (native con-
formation) may have slightly changed after encapsulation
and recovery processes by protocols A, B1, B2, B4, and C. A
possible explanation is that insulin could be linked toReis ealginate polymer altering protein structure, though not
representing denaturation or loss of insulin activity. Finally,
different CD data were observed for protocol B3. The
features of the spectra for reference solution and protocol B3
were similar, and indicated that insulin recovered from
alginate particles using protocol B3, after 2 h of contact in
PBS, retained its secondary structure.t al.: Design and Recovery of Insulin-Loaded Alginate Microparticles 987
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Conclusions
Insulin-loaded alginate microparticles with small size were
successfully prepared by an emulsification method using
internal gelation technology. The recovery step is proble-
matic, and thus centrifugation coupled with dehydrating
solvents was applied to improve RY and insulin encapsula-
tion efficiency (protocol B). The presence of solvents also
enables particle recovery at lower centrifugal force. Acetate-
buffer-acetone-isopropanol-hexane coupled with lower
speed rate of centrifugation decreased the size of the
particles, and increased the RY and the encapsulation
efficiency of insulin, but the morphology of insulin-loaded
alginate particles was slightly altered. The secondary
structure of insulin was also tested after encapsulation
and no effects on secondary structure were seen for insulin
after encapsulation and recovery process by protocol B3.
This methodology of producing microparticles was gentle
for insulin and potentially other proteins, as seen by
RP-HPLC /HPLC-Mass and CD analysis, and is easily
manipulated with important application to the pharma-
ceutical field. Results describing the biological activity of
released insulin will be the subject of published work in the
near future.
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